IRON2-Hyp (2019-2022)

IRON2-Hyp (2019-2022)

« Innovative Radiopharmaceuticals in Oncology and Neurology »

(Co-funding Labex IRON2)

This project aims to develop innovative approaches targeting hypoxia based on new molecular targets and/or new radiopharmaceuticals. This project will develop fundamental (chemistry, biology) and translational (preclinical to clinical) multidisciplinary research mainly according to two approaches:
   1/ approaches related to nitroimidazole-based radiotracers
   2/ molecular approaches targeting the HIF transcription factor, the most recognized molecular “sensor” of hypoxia.
This project aims to provide several proofs of concept of new hypoxia-based markers and treatments at the radiochemistry, preclinical and/or clinical stages.

Partner : ISTCT (Caen, FR)